These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 39367952)
1. Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model. Tachi T; Kijima N; Kuroda H; Ikeda S; Murakami K; Nakagawa T; Yaga M; Nakagawa K; Utsugi R; Hirayama R; Okita Y; Kagawa N; Kishima H; Imai C; Hosen N Cancer Immunol Immunother; 2024 Oct; 73(12):256. PubMed ID: 39367952 [TBL] [Abstract][Full Text] [Related]
2. B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. Nehama D; Di Ianni N; Musio S; Du H; Patané M; Pollo B; Finocchiaro G; Park JJH; Dunn DE; Edwards DS; Damrauer JS; Hudson H; Floyd SR; Ferrone S; Savoldo B; Pellegatta S; Dotti G EBioMedicine; 2019 Sep; 47():33-43. PubMed ID: 31466914 [TBL] [Abstract][Full Text] [Related]
3. CD19 CAR-expressing iPSC-derived NK cells effectively enhance migration and cytotoxicity into glioblastoma by targeting to the pericytes in tumor microenvironment. Kong D; Kwon D; Moon B; Kim DH; Kim MJ; Choi J; Kang KS Biomed Pharmacother; 2024 May; 174():116436. PubMed ID: 38508081 [TBL] [Abstract][Full Text] [Related]
4. B7-H3-Targeting Chimeric Antigen Receptors Epstein-Barr Virus-specific T Cells Provides a Tumor Agnostic Off-The-Shelf Therapy Against B7-H3-positive Solid Tumors. Yeo SP; Kua L; Tan JW; Lim JK; Wong FH; Santos MD; Poh CM; Goh AX; Koh XY; Zhou X; Rajarethinam R; Chen Q; Her Z; Horak ID; Low L; Tan KW Cancer Res Commun; 2024 Jun; 4(6):1410-1429. PubMed ID: 38717140 [TBL] [Abstract][Full Text] [Related]
5. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma. Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245 [TBL] [Abstract][Full Text] [Related]
6. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. Liu J; Yang S; Cao B; Zhou G; Zhang F; Wang Y; Wang R; Zhu L; Meng Y; Hu C; Liang H; Lin X; Zhu K; Chen G; Luo KQ; Di L; Zhao Q J Hematol Oncol; 2021 Jan; 14(1):21. PubMed ID: 33514401 [TBL] [Abstract][Full Text] [Related]
7. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. Majzner RG; Theruvath JL; Nellan A; Heitzeneder S; Cui Y; Mount CW; Rietberg SP; Linde MH; Xu P; Rota C; Sotillo E; Labanieh L; Lee DW; Orentas RJ; Dimitrov DS; Zhu Z; Croix BS; Delaidelli A; Sekunova A; Bonvini E; Mitra SS; Quezado MM; Majeti R; Monje M; Sorensen PHB; Maris JM; Mackall CL Clin Cancer Res; 2019 Apr; 25(8):2560-2574. PubMed ID: 30655315 [TBL] [Abstract][Full Text] [Related]
8. An Oncolytic Virus Expressing IL15/IL15Rα Combined with Off-the-Shelf EGFR-CAR NK Cells Targets Glioblastoma. Ma R; Lu T; Li Z; Teng KY; Mansour AG; Yu M; Tian L; Xu B; Ma S; Zhang J; Barr T; Peng Y; Caligiuri MA; Yu J Cancer Res; 2021 Jul; 81(13):3635-3648. PubMed ID: 34006525 [TBL] [Abstract][Full Text] [Related]
9. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. Du H; Hirabayashi K; Ahn S; Kren NP; Montgomery SA; Wang X; Tiruthani K; Mirlekar B; Michaud D; Greene K; Herrera SG; Xu Y; Sun C; Chen Y; Ma X; Ferrone CR; Pylayeva-Gupta Y; Yeh JJ; Liu R; Savoldo B; Ferrone S; Dotti G Cancer Cell; 2019 Feb; 35(2):221-237.e8. PubMed ID: 30753824 [TBL] [Abstract][Full Text] [Related]
10. Directing B7-H3 chimeric antigen receptor T cell homing through IL-8 induces potent antitumor activity against pediatric sarcoma. Lake JA; Woods E; Hoffmeyer E; Schaller KL; Cruz-Cruz J; Fernandez J; Tufa D; Kooiman B; Hall SC; Jones D; Hayashi M; Verneris MR J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39043604 [TBL] [Abstract][Full Text] [Related]
11. Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. Theruvath J; Sotillo E; Mount CW; Graef CM; Delaidelli A; Heitzeneder S; Labanieh L; Dhingra S; Leruste A; Majzner RG; Xu P; Mueller S; Yecies DW; Finetti MA; Williamson D; Johann PD; Kool M; Pfister S; Hasselblatt M; Frühwald MC; Delattre O; Surdez D; Bourdeaut F; Puget S; Zaidi S; Mitra SS; Cheshier S; Sorensen PH; Monje M; Mackall CL Nat Med; 2020 May; 26(5):712-719. PubMed ID: 32341579 [TBL] [Abstract][Full Text] [Related]
12. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors. Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008 [No Abstract] [Full Text] [Related]
13. Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia. Lichtman EI; Du H; Shou P; Song F; Suzuki K; Ahn S; Li G; Ferrone S; Su L; Savoldo B; Dotti G Clin Cancer Res; 2021 Jun; 27(11):3141-3153. PubMed ID: 33531429 [TBL] [Abstract][Full Text] [Related]
14. HER2-targeting CAR-T cells show highly efficient anti-tumor activity against glioblastoma both in vitro and in vivo. Li X; Zhao L; Li W; Gao P; Zhang N Genes Immun; 2024 Jun; 25(3):201-208. PubMed ID: 38702509 [TBL] [Abstract][Full Text] [Related]
15. B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo. Zhang Q; Zhang Z; Liu G; Li D; Gu Z; Zhang L; Pan Y; Cui X; Wang L; Liu G; Tian X; Zhang Z BMC Cancer; 2022 Nov; 22(1):1124. PubMed ID: 36320072 [TBL] [Abstract][Full Text] [Related]
16. Redirecting B7-H3.CAR T Cells to Chemokines Expressed in Osteosarcoma Enhances Homing and Antitumor Activity in Preclinical Models. Talbot LJ; Chabot A; Ross AB; Beckett A; Nguyen P; Fleming A; Chockley PJ; Shepphard H; Wang J; Gottschalk S; DeRenzo C Clin Cancer Res; 2024 Oct; 30(19):4434-4449. PubMed ID: 39101835 [TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting. Ventin M; Cattaneo G; Arya S; Jia J; Gelmi MC; Sun Y; Maggs L; Ksander BR; Verdijk RM; Boland GM; Jenkins RW; Haq R; Jager MJ; Wang X; Ryeom S; Ferrone CR Clin Cancer Res; 2024 Aug; 30(15):3243-3258. PubMed ID: 38767611 [TBL] [Abstract][Full Text] [Related]
18. Identification of genetic modifiers enhancing B7-H3-targeting CAR T cell therapy against glioblastoma through large-scale CRISPRi screening. Li X; Sun S; Zhang W; Liang Z; Fang Y; Sun T; Wan Y; Ma X; Zhang S; Xu Y; Tian R J Exp Clin Cancer Res; 2024 Apr; 43(1):95. PubMed ID: 38561797 [TBL] [Abstract][Full Text] [Related]
19. TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors. Nishimura CD; Corrigan D; Zheng XY; Galbo PM; Wang S; Liu Y; Wei Y; Suo L; Cui W; Mercado N; Zheng D; Zhang CC; Zang X Sci Adv; 2024 May; 10(19):eadk1857. PubMed ID: 38718110 [TBL] [Abstract][Full Text] [Related]
20. A Novel Orthotopic Implantation Technique for Osteosarcoma Produces Spontaneous Metastases and Illustrates Dose-Dependent Efficacy of B7-H3-CAR T Cells. Talbot LJ; Chabot A; Funk A; Nguyen P; Wagner J; Ross A; Tillman H; Davidoff A; Gottschalk S; DeRenzo C Front Immunol; 2021; 12():691741. PubMed ID: 34211478 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]